In a simple definition, cancer is a disease of the cells, which is caused by gene mutations. For a proportion of patients, including women with hormone receptor positive breast cancer, gene expression profiling has a substantial impact on treatment decision-making by determining which patients might—or might not—respond to particular treatment options.
A group of melanoma experts, joined by three advocacy groups focused on melanoma, has engaged FDA in a public discussion of the challenges of developing new drugs in the refractory setting and the role crossover can play in such trials.
